The launch of our prostate cancer prevention education and research platform demonstrates the latest way that GSK is standing up to cancer.
Philadelphia (PRWEB) October 15, 2008
GSK announced today that it will team with The V Foundation® and Stand Up to Cancer™ to create a major educational initiative focusing on the impact of prostate cancer in the United States and how men can better manage their risk. This will complement GSK's $10 million sponsorship of Stand Up To Cancer, which supports cancer awareness and research efforts.
"With our support of Stand Up To Cancer, we stand with the entertainers, foundations, physicians, media and scientists who have joined together to raise money for "dream teams" of researchers whose work will accelerate the effort to end cancer as we know it," said David Pernock, GSK U.S. Senior Vice President of Pharmaceuticals and Vaccines. "The launch of our prostate cancer prevention education and research platform demonstrates the latest way that GSK is standing up to cancer."
Paolo Paoletti, Senior Vice President, GSK Oncology Research and Development, further commented that the company's prostate cancer prevention campaign aligns well with GSK's focus on oncology. "GSK has established its commitment to oncology through a substantial investment in research and development, and the introduction of treatments for breast cancer, lymphoma, ovarian and lung cancers. In addition to treating cancer, we are also focused on prevention, and are conducting one of the largest prostate-cancer prevention trials ever undertaken."
More than 200,000 men in the United States are diagnosed with prostate cancer each year, and it is among the leading causes of cancer deaths among U.S. men.
Later this year, GSK, Stand Up To Cancer, Entertainment Industry Foundation (EIF)™ and The V Foundation will host a kick-off event in New York City for Life: Interrupted -- Stand Up to Prostate Cancer. More program details will be released soon.
"On behalf of everyone at Stand Up To Cancer, we are tremendously grateful to GlaxoSmithKline for the support it has provided to make this historic event possible," said Lisa Paulsen, President & CEO of EIF, the 501(c) (3) charitable organization for the television and film business that serves as the fiduciary behind Stand Up To Cancer. "GlaxoSmithKline's commitment to fighting cancer, and specifically educating men and their families on the reality and risks of prostate cancer, will take us a step closer to defeat this life interrupting disease."
About Stand Up To Cancer
STAND UP TO CANCER (SU2C) was created to galvanize the public around this goal: end cancer's reign as a leading cause of death by raising funds to accelerate ground-breaking research that will get new therapies to patients quickly. On September 5, 2008 (8pm EDT and PDT) the three major networks, ABC, CBS and NBC, donated one hour of simultaneous commercial-free primetime for a nationally-televised fundraising event. From the Stand Up To Cancer launch on May 28, 2008, through September 5, 2008's historic simultaneous commercial-free telecast, the initiative has raised more than $100 million to accelerate ground-breaking research and bring new therapies to patients more quickly. Visit http://www.su2c.org for more information.
About the Entertainment Industry Foundation
The Entertainment Industry Foundation (EIF), the collective philanthropic organization for the television and film businesses, has distributed hundreds of millions of dollars to support programs addressing critical health, education and social issues.
About The V Foundation
The V Foundation for Cancer Research was founded in 1993 by ESPN and the late Jim Valvano, legendary North Carolina State basketball coach and ESPN commentator. Since 1993, The Foundation has raised more than $80 million to fund cancer research grants nationwide. It awards 100 percent of all new direct cash donations and net proceeds of events directly to cancer research and related programs. The Foundation, which has received five consecutive top 4-star ratings from Charity Navigator, awards grants through a competitive awards process strictly supervised by a Scientific Advisory Board. For more information on The V Foundation or to make a donation, please visit http://www.jimmyv.org.
About GSK in Oncology
GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary 'bench to bedside' approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centers. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
US Media enquiries:
Rob Perry (215) 751-7583
Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
Sarah Alspach (215) 751 7709
US Analyst/Investor enquiries
Tom Curry: (215) 751 5419
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.
Registered in England & Wales:
980 Great West Road